Benjamin M Jacobs1, Gavin Giovannoni2, Jack Cuzick1, Ruth Dobson3. 1. Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. 2. Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University, London, UK/Blizard Institute, Queen Mary University of London, London, UK/Royal London Hospital, London, UK. 3. Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK/Royal London Hospital, London, UK.
Abstract
BACKGROUND: Epstein-Barr virus (EBV) infection is thought to play a central role in the development of multiple sclerosis (MS). If causal, it represents a target for interventions to reduce MS risk. OBJECTIVE: To examine the evidence for interaction between EBV and other risk factors, and explore mechanisms via which EBV infection may influence MS risk. METHODS: Pubmed was searched using the terms 'multiple sclerosis' AND 'Epstein Barr virus', 'multiple sclerosis' AND EBV, 'clinically isolated syndrome' AND 'Epstein Barr virus' and 'clinically isolated syndrome' AND EBV. All abstracts were reviewed for possible inclusion. RESULTS: A total of 262 full-text papers were reviewed. There was evidence of interaction on the additive scale between anti-EBV antibody titre and HLA genotype (attributable proportion due to interaction (AP) = 0.48, p < 1 × 10-4). Previous infectious mononucleosis (IM) was associated with increased odds ratio (OR) of MS in HLA-DRB1*1501 positive but not HLA-DRB1*1501 negative persons. Smoking was associated with a greater risk of MS in those with high anti-EBV antibodies (OR = 2.76) but not low anti-EBV antibodies (OR = 1.16). No interaction between EBV and risk factors was found on a multiplicative scale. CONCLUSION: EBV appears to interact with at least some established MS risk factors. The mechanism via which EBV influences MS risk remains unknown.
BACKGROUND:Epstein-Barr virus (EBV) infection is thought to play a central role in the development of multiple sclerosis (MS). If causal, it represents a target for interventions to reduce MS risk. OBJECTIVE: To examine the evidence for interaction between EBV and other risk factors, and explore mechanisms via which EBVinfection may influence MS risk. METHODS: Pubmed was searched using the terms 'multiple sclerosis' AND 'Epstein Barr virus', 'multiple sclerosis' AND EBV, 'clinically isolated syndrome' AND 'Epstein Barr virus' and 'clinically isolated syndrome' AND EBV. All abstracts were reviewed for possible inclusion. RESULTS: A total of 262 full-text papers were reviewed. There was evidence of interaction on the additive scale between anti-EBV antibody titre and HLA genotype (attributable proportion due to interaction (AP) = 0.48, p < 1 × 10-4). Previous infectious mononucleosis (IM) was associated with increased odds ratio (OR) of MS in HLA-DRB1*1501 positive but not HLA-DRB1*1501 negative persons. Smoking was associated with a greater risk of MS in those with high anti-EBV antibodies (OR = 2.76) but not low anti-EBV antibodies (OR = 1.16). No interaction between EBV and risk factors was found on a multiplicative scale. CONCLUSION:EBV appears to interact with at least some established MS risk factors. The mechanism via which EBV influences MS risk remains unknown.
Authors: Trine Rasmussen Nielsen; Klaus Rostgaard; Nete Munk Nielsen; Nils Koch-Henriksen; Sven Haahr; Per Soelberg Sørensen; Henrik Hjalgrim Journal: Arch Neurol Date: 2007-01
Authors: Emilie Sundqvist; Peter Sundström; Magdalena Lindén; Anna Karin Hedström; Francesca Aloisi; Jan Hillert; Ingrid Kockum; Lars Alfredsson; Tomas Olsson Journal: Neurology Date: 2012-08-29 Impact factor: 9.910
Authors: Amy M Lavery; Bradley N Collins; Amy T Waldman; Chantelle N Hart; Amit Bar-Or; Ruth Ann Marrie; Douglas Arnold; Julia O'Mahony; Brenda Banwell Journal: Mult Scler Date: 2018-02-02 Impact factor: 6.312
Authors: Julia Pakpoor; Giulio Disanto; Jennifer E Gerber; Ruth Dobson; Ute C Meier; Gavin Giovannoni; Sreeram V Ramagopalan Journal: Mult Scler Date: 2012-06-11 Impact factor: 6.312
Authors: T R Nielsen; K Rostgaard; J Askling; R Steffensen; A Oturai; C Jersild; N Koch-Henriksen; P S Sørensen; H Hjalgrim Journal: Mult Scler Date: 2009-01-19 Impact factor: 6.312
Authors: Kathrine E Attfield; Lise Torp Jensen; Max Kaufmann; Manuel A Friese; Lars Fugger Journal: Nat Rev Immunol Date: 2022-05-04 Impact factor: 53.106
Authors: Ashvin Kuri; Benjamin Meir Jacobs; Nikki Vickaryous; Julia Pakpoor; Jaap Middeldorp; Gavin Giovannoni; Ruth Dobson Journal: BMC Public Health Date: 2020-06-12 Impact factor: 3.295